Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 17/20 | 0.50 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.48 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL386624 | 0.83 | ENPP2 (0.55) | PTGS2PTGS1 | |
| SCHEMBL15599291 | 0.81 | NPC1 (0.48) | — | |
| SCHEMBL14167750 | 0.80 | KDM4E (0.49) | PTGS2PTGS1 | |
| SCHEMBL22807037 | 0.80 | PTGS2 (0.56) | PTGS2PTGS1 | |
| SCHEMBL4457504 | 0.79 | PTGS2 (0.44) | PTGS2PTGS1 | |
| SCHEMBL28153627 | 0.78 | PTGS2 (0.46) | PTGS2PTGS1 | |
| SCHEMBL738443 | 0.77 | CCR1 (0.46) | — | |
| SCHEMBL15257349 | 0.75 | PTGS2 (0.60) | PTGS2PTGS1 | |
| SCHEMBL13402229 | 0.74 | NPC1 (0.48) | — | |
| SCHEMBL10000244 | 0.74 | NPC1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2059517-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | Biovitrum AB (publ) (SE) | 2009-05-20 | — | — | EP | disclosed |
| US-20080103141-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103141-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| US-20080103141-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
| WO-2008025800-A1 | PYRIMIDINE COMPOUNDS FOR TREATING GPR119 RELATED DISORDERS | BIOVITRUM AB (PUBL) (SE) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103141-A1 | New compounds | GPR119, GPR3, GPR4 | PTGS2 1169/4885PTGS1 1205/4885GPR119 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.